BCRX Healthcare

BioCryst Pharmaceuticals, Inc.

$8.57+3.88%

Price as of close on Nov 3, 2026 · Financials updated Oct 6, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Market cap: 2.2B USD
Enterprise value: 2.0B USD
Full-time employees: 435

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers on debt, liquidity or share-price swings

Ranks #949 of 1,157 healthcare companies (bottom 19%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
BioCryst Pharmaceuticals's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Shareholders being diluted. Shares outstanding up 36% from December 2022 to July 2026.
BioCryst Pharmaceuticals had 36% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.BioCryst Pharmaceuticals had 36% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, BioCryst Pharmaceuticals looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 92% of peers, at an operating loss.
Revenue grew faster than 92% of peers, but the business runs at an operating loss (margin -33%).

StockQuotient Score

32/ 100

Oct 5 32 → Nov 4 32

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-17.6%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-14.2%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield17.0%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingOutlier capped at sector 5th/95th percentile20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-20.7%

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

89/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 6.2%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth45.3%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 4.69Sector median: 0.0584 · MAD: 0.0840

Revenue growth68.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 6.43Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

22/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 9.8 points to -33.3%

Why

Weaker than most peers on:

▼ ROA
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-33.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.31Sector median: 0.0706 · MAD: 0.1217

Return on assets-69.0%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537

Return on invested capital1147.3%

Yahoo Finance fallback · SEC operating income or invested capital unavailable · trailing 12 monthsOutlier capped at sector 5th/95th percentile33% base weight · Z-score 3.81Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin97.8%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equityUnavailable

Missing · left out of the scoreInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.55

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.23Sector median: 0.6250 · MAD: 0.3380

Current ratio2.32×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.19Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about BioCryst Pharmaceuticals

Is BioCryst Pharmaceuticals getting weaker?: Its latest SEC filing (Aug 5, 2026) got stronger: operating margin rose 9.8 points to -33.3%. Its overall score is unchanged at 32/100 since Oct 28, 2026.
How is BioCryst Pharmaceuticals valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -17.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -17.6% vs peers 1.5% (weaker than 100% of peers).
Is BioCryst Pharmaceuticals growing?: Yes, faster than most of its peers. Growth scores 89/100 against 1,393 healthcare peers. 3-year revenue growth 45.3% vs a peer median of 5.8% (stronger than 92% of peers).3-year revenue growth 45.3% vs peers 5.8% (stronger than 92% of peers).
How profitable is BioCryst Pharmaceuticals?: Less profitable than most of its peers. Profitability scores 22/100 against 1,393 healthcare peers. Return on invested capital 1147.3% vs a peer median of 4.7% (stronger than 95% of peers).Return on invested capital 1147.3% vs peers 4.7% (stronger than 95% of peers). Return on assets -69.0% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -69.0% vs peers 1.7% (weaker than 100% of peers).
How risky is BioCryst Pharmaceuticals?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Operating margin rose 9.8 points to -33.3%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	885.7M USD	940.6M USD	+6.2%
Net income (12 months)	−458.0M USD	−384.7M USD	−16.0%
Operating margin	-43.1%	-33.3%	+9.8 pts
Free cash flow (12 months)	310.4M USD	373.4M USD	+20.3%
Debt	395.2M USD	395.4M USD	+0.1%
Cash	171.6M USD	155.0M USD	−9.7%
Shares outstanding	254.2M	255.5M	+0.5%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Drug Manufacturers - Specialty & Generic · 27 companies

Valuations in Drug Manufacturers - Specialty & Generic are within their usual range since Jun 2020.

45% of months since Jun 2020 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +8% vs the whole market, against a usual +36%.

Jun 2020Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	95.4%	97.6%	98.6%	97.3%	97.8%	▲ 0.5 pts
Operating margin	-113.1%	-54.8%	-31.3%	-0.6%	39.0%	▲ 40 pts
Net margin	-117.1%	-91.2%	-68.4%	-19.7%	30.2%	▲ 50 pts
Return on assets (ROA)	-31.3%	-44.9%	-43.8%	-18.1%	51.3%	▲ 69 pts
Free cash flow margin	-92.0%	-60.3%	-29.4%	-11.8%	39.4%	▲ 51 pts
Current ratio	5.46×	4.90×	3.31×	2.63×	2.06×	▼ 22%
Quick ratio	5.31×	4.63×	3.12×	2.58×	2.03×	▼ 21%
Interest coverage	-3.00×	-1.50×	-0.96×	-0.03×	4.32×	▲ >999%

BCRX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers on debt, liquidity or share-price swings

Ranks #949 of 1,157 healthcare companies (bottom 19%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

BioCryst Pharmaceuticals's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Shareholders being diluted. Shares outstanding up 36% from December 2022 to July 2026.

BioCryst Pharmaceuticals had 36% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.BioCryst Pharmaceuticals had 36% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, BioCryst Pharmaceuticals looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 92% of peers, at an operating loss.

Revenue grew faster than 92% of peers, but the business runs at an operating loss (margin -33%).

Questions investors ask about BioCryst Pharmaceuticals

Is BioCryst Pharmaceuticals getting weaker?

Its latest SEC filing (Aug 5, 2026) got stronger: operating margin rose 9.8 points to -33.3%. Its overall score is unchanged at 32/100 since Oct 28, 2026.

How is BioCryst Pharmaceuticals valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -17.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -17.6% vs peers 1.5% (weaker than 100% of peers).

Is BioCryst Pharmaceuticals growing?

Yes, faster than most of its peers. Growth scores 89/100 against 1,393 healthcare peers. 3-year revenue growth 45.3% vs a peer median of 5.8% (stronger than 92% of peers).3-year revenue growth 45.3% vs peers 5.8% (stronger than 92% of peers).

How profitable is BioCryst Pharmaceuticals?

Less profitable than most of its peers. Profitability scores 22/100 against 1,393 healthcare peers. Return on invested capital 1147.3% vs a peer median of 4.7% (stronger than 95% of peers).Return on invested capital 1147.3% vs peers 4.7% (stronger than 95% of peers). Return on assets -69.0% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -69.0% vs peers 1.7% (weaker than 100% of peers).

How risky is BioCryst Pharmaceuticals?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

885.7M USD

940.6M USD

+6.2%

Net income (12 months)

−458.0M USD

−384.7M USD

−16.0%

Operating margin

-43.1%

-33.3%

+9.8 pts

Free cash flow (12 months)

310.4M USD

373.4M USD

+20.3%

Debt

395.2M USD

395.4M USD

+0.1%

Cash

171.6M USD

155.0M USD

−9.7%

Shares outstanding

254.2M

255.5M

+0.5%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

95.4%

97.6%

98.6%

97.3%

97.8%

▲ 0.5 pts

Operating margin

-113.1%

-54.8%

-31.3%

-0.6%

39.0%

▲ 40 pts

Net margin

-117.1%

-91.2%

-68.4%

-19.7%

30.2%

▲ 50 pts

Return on assets (ROA)

-31.3%

-44.9%

-43.8%

-18.1%

51.3%

▲ 69 pts

Free cash flow margin

-92.0%

-60.3%

-29.4%

-11.8%

39.4%

▲ 51 pts

Current ratio

5.46×

4.90×

3.31×

2.63×

2.06×

▼ 22%

Quick ratio

5.31×

4.63×

3.12×

2.58×

2.03×

▼ 21%

Interest coverage

-3.00×

-1.50×

-0.96×

-0.03×

4.32×

▲ >999%